BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38237887)

  • 1. A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
    Chen L; Xu G; Song X; Zhang L; Chen C; Xiang G; Wang S; Zhang Z; Wu F; Yang X; Zhang L; Ma X; Yu J
    Cancer Lett; 2024 Feb; 583():216635. PubMed ID: 38237887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial cells promote triple-negative breast cancer cell metastasis
    Zhang W; Xu J; Fang H; Tang L; Chen W; Sun Q; Zhang Q; Yang F; Sun Z; Cao L; Wang Y; Guan X
    FASEB J; 2018 Jan; 32(1):276-288. PubMed ID: 28899878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.
    Norton KA; Wallace T; Pandey NB; Popel AS
    BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR5-Mediated Signaling Is Involved in Invasion of Glioblastoma Cells in Its Microenvironment.
    Novak M; Koprivnikar Krajnc M; Hrastar B; Breznik B; Majc B; Mlinar M; Rotter A; Porčnik A; Mlakar J; Stare K; Pestell RG; Lah Turnšek T
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma.
    González-Arriagada WA; Coletta RD; Lozano-Burgos C; García C; Maripillán J; Alcayaga-Miranda F; Godínez-Pacheco B; Oyarce-Pezoa S; Martínez-Flores R; García IE
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17335-17346. PubMed ID: 37831273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential to target CCL5/CCR5 in breast cancer.
    Velasco-Velázquez M; Xolalpa W; Pestell RG
    Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
    Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
    Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
    Front Immunol; 2019; 10():757. PubMed ID: 31031757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.
    Kranjc MK; Novak M; Pestell RG; Lah TT
    Radiol Oncol; 2019 Nov; 53(4):397-406. PubMed ID: 31747383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
    Casagrande N; Borghese C; Visser L; Mongiat M; Colombatti A; Aldinucci D
    Haematologica; 2019 Mar; 104(3):564-575. PubMed ID: 30309853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis.
    Pervaiz A; Zepp M; Georges R; Bergmann F; Mahmood S; Faiza S; Berger MR; Adwan H
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):73-91. PubMed ID: 32902795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin C Inhibits Triple-Negative Breast Cancer Metastasis by Affecting the Expression of YAP1 and Synaptopodin 2.
    Gan L; Camarena V; Mustafi S; Wang G
    Nutrients; 2019 Dec; 11(12):. PubMed ID: 31817810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
    Song X; Zhou X; Qin Y; Yang J; Wang Y; Sun Z; Yu K; Zhang S; Liu S
    Int J Mol Med; 2018 Jul; 42(1):579-588. PubMed ID: 29693154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells.
    Singh SK; Mishra MK; Eltoum IA; Bae S; Lillard JW; Singh R
    Sci Rep; 2018 Jan; 8(1):1323. PubMed ID: 29358632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
    Aldinucci D; Casagrande N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.
    Pervaiz A; Zepp M; Mahmood S; Ali DM; Berger MR; Adwan H
    Cell Oncol (Dordr); 2019 Feb; 42(1):93-106. PubMed ID: 30456574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
    Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
    Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia.
    Lin S; Wan S; Sun L; Hu J; Fang D; Zhao R; Yuan S; Zhang L
    Cancer Sci; 2012 May; 103(5):904-12. PubMed ID: 22380870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.
    Sax MJ; Gasch C; Athota VR; Freeman R; Rasighaemi P; Westcott DE; Day CJ; Nikolic I; Elsworth B; Wei M; Rogers K; Swarbrick A; Mittal V; Pouliot N; Mellick AS
    Oncotarget; 2016 Dec; 7(51):85437-85449. PubMed ID: 27863423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.